Highlight
– The NEWTON-CABG CardioLink-5 was a randomized, double-blind, placebo-controlled trial evaluating evolocumab for preventing saphenous vein graft (SVG) failure after coronary artery bypass grafting (CABG).
– Despite achieving a substantial 48.4% placebo-adjusted reduction in LDL cholesterol (LDL-C), evolocumab did not reduce SVG disease rate at 24 months compared to placebo.
– The findings suggest that LDL-C lowering beyond guideline-recommended statin therapy does not significantly influence the pathophysiology of early SVG failure.
– Evolocumab was well tolerated with similar adverse event rates between treatment and placebo groups.
